Expertise, Role and Activity
The Institute of Radiopharmaceutical Cancer Research at HZDR is focused on research and development towards radiolabelled compounds and immunotherapeutics including antibody derivatives and cellular immunotherapies based on chimeric antigen receptor (CARs) for the therapy and diagnosis of tumors and has a key role in WP5. HZDR has a critical role in the generation of B-specific immunotherapies and has been in consortium with other partners from the consortium like Prof. Karen Vanhoorelbeke and Dr. Nick Geukens from KUL.
Michael Bachmann
Prof. Dr. Michael Bachmann is heading the institute of Radiopharmaceutical Cancer Research and full professor at the medical faculty of the Technische Universität Dresden and one of the Directors of the National Center for Tumor Diseases. He is an expert in developing immunotheranostics, including bispecific antibodies and cellular immunotherapies.
Anja Feldmann
Dr. Anja Feldmann head of Department Radioimmunology of the Institute of Radiopharmaceutical Cancer Research at HZDR is focussing on the development of immunotheranostic strategies for the therapy and diagnosis of tumors, infectious, autoimmune and inflammatory diseases including bispecific antibodies, antibody derivatives and cellular chimeric antigen receptor (CAR)-based immunotherapies as well as non/radio-labelled target molecules (based on antibodies, peptides and small molecules) for Adapter CAR immunotherapy (UniCAR, RevCAR), diagnostic imaging and endoradiotherapy.
Claudia Arndt
Dr. Claudia Arndt is leading the tandem research group “Engineered T-cells for personalized cancer therapy” in the Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research at HZDR. With her expertise in T cell engineering and target module development, she will play a critical role in supporting the HZDR team in establishing new ABC-directed adaptor CAR-T platforms in WP5.
Alexandra von Jutrzenka
Dr. Alexandra von Jutrzenka-Trzebiatowski is a postdoctoral researcher in the Department of Radioimmunology at the Institute of Radiopharmaceutical Cancer Research, HZDR. With proven expertise in protein engineering and genetic modification of T cells, she is a driving force in WP5, advancing the development of adaptor CAR-T cells aimed at creating effective therapeutic solutions for cardiovascular disorders.
All the Consortium
